118 related articles for article (PubMed ID: 15336816)
1. Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study.
Nakagawa T; Kobayashi T; Awata N; Sato S; Reiber JH; Nakajima H; Toyama YN; Hiraoka H; Kato O; Kirino M; Kobayashi T; Takeda Y; Yachiku K; Iida M; Itoh T; Shibata N
Int J Cardiol; 2004 Oct; 97(1):107-14. PubMed ID: 15336816
[TBL] [Abstract][Full Text] [Related]
2. Preventing angiographic progression of coronary atherosclerosis with pravastatin.
Daida H; Ouchi Y; Saito Y; Yamada N; Nishide T; Mokuno H; Kurata T; Sato H; Eto M; Ako JY; Tango T; Yamaguchi H;
J Atheroscler Thromb; 2003; 10(1):25-31. PubMed ID: 12621161
[TBL] [Abstract][Full Text] [Related]
3. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group.
Tamura A; Mikuriya Y; Nasu M
Am J Cardiol; 1997 Apr; 79(7):893-6. PubMed ID: 9104901
[TBL] [Abstract][Full Text] [Related]
4. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).
Klerkx AH; de Grooth GJ; Zwinderman AH; Jukema JW; Kuivenhoven JA; Kastelein JJ
Eur J Clin Invest; 2004 Jan; 34(1):21-8. PubMed ID: 14984434
[TBL] [Abstract][Full Text] [Related]
5. Angiographic intervention trial using HMG CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma in West Japan (ATHEROMA study): rationale, design and baseline.
Kawaguchi A; Mitsudo K; Nobuyoshi M; Minamino R; Hayasaki K; Nakashima M; Yamamoto A;
J Cardiovasc Risk; 2002 Feb; 9(1):7-16. PubMed ID: 11984212
[TBL] [Abstract][Full Text] [Related]
6. Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group.
Cobbaert C; Jukema JW; Zwinderman AH; Withagen AJ; Lindemans J; Bruschke AV
J Am Coll Cardiol; 1997 Nov; 30(6):1491-9. PubMed ID: 9362407
[TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
[TBL] [Abstract][Full Text] [Related]
8. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema JW; Bruschke AV; van Boven AJ; Reiber JH; Bal ET; Zwinderman AH; Jansen H; Boerma GJ; van Rappard FM; Lie KI
Circulation; 1995 May; 91(10):2528-40. PubMed ID: 7743614
[TBL] [Abstract][Full Text] [Related]
9. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
Nissen SE
Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
[TBL] [Abstract][Full Text] [Related]
10. Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin.
Alipour A; Cabezas MC; Elte JW; Vallvé JC; Ribalta J; Zwinderman AH; Defesche JC; Jukema JW
Atherosclerosis; 2011 Mar; 215(1):125-9. PubMed ID: 21211797
[TBL] [Abstract][Full Text] [Related]
11. Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study.
Yokoi H; Nobuyoshi M; Mitsudo K; Kawaguchi A; Yamamoto A;
Circ J; 2005 Aug; 69(8):875-83. PubMed ID: 16041153
[TBL] [Abstract][Full Text] [Related]
12. The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
Cashin-Hemphill L; Kramsch DM; Azen SP; DeMets D; DeBoer LW; Hwang I; Vailas L; Hirsch LJ; Mack WJ; DeBoer L
Online J Curr Clin Trials; 1992 Oct; Doc No 26():[9897 words; 83 paragraphs]. PubMed ID: 1343613
[TBL] [Abstract][Full Text] [Related]
13. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
[TBL] [Abstract][Full Text] [Related]
14. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
Arntz HR; Agrawal R; Wunderlich W; Schnitzer L; Stern R; Fischer F; Schultheiss HP
Am J Cardiol; 2000 Dec; 86(12):1293-8. PubMed ID: 11113401
[TBL] [Abstract][Full Text] [Related]
16. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico).
Ital Heart J; 2000 Dec; 1(12):810-20. PubMed ID: 11302109
[TBL] [Abstract][Full Text] [Related]
17. The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study.
Sakamoto K; Sakamoto T; Ogawa H;
Clin Ther; 2006 Jul; 28(7):1012-21. PubMed ID: 16990079
[TBL] [Abstract][Full Text] [Related]
18. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
Schoenhagen P; Tuzcu EM; Apperson-Hansen C; Wang C; Wolski K; Lin S; Sipahi I; Nicholls SJ; Magyar WA; Loyd A; Churchill T; Crowe T; Nissen SE
Circulation; 2006 Jun; 113(24):2826-34. PubMed ID: 16769916
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis.
Agema WR; Wouter Jukema J; de Maat MP; Zwinderman AH; Kastelein JJ; Rabelink TJ; van der Wall EE
Thromb Haemost; 2004 May; 91(5):986-90. PubMed ID: 15116260
[TBL] [Abstract][Full Text] [Related]
20. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
de Groot E; Jukema JW; van Boven AJ; Reiber JH; Zwinderman AH; Lie KI; Ackerstaff RA; Bruschke AV
Am J Cardiol; 1995 Sep; 76(9):40C-46C. PubMed ID: 7572685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
